Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% ...

TD Cowen analyst Yaron Werber reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s shares opened today at $278.85.

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

The Dow Jones Industrial Average is rallying Tuesday afternoon with shares of Amgen and Merck delivering the strongest returns for the blue-chip average.

Buoyed by positive gains for shares of Amgen and Merck, the Dow Jones Industrial Average is climbing Tuesday morning. Supported by world-class markets data from Dow Jones and FactSet, and partnering ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Responding to the European Commission’s call for evidence, Biovia says regulatory delays, fragmented markets, and lack of capital are costing Europe its biotech edge.

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...